http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2234962-C2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-04 |
| filingDate | 2002-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2004-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b098c98cf5d9b3448e9f77cd3ecf841e |
| publicationDate | 2004-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2234962-C2 |
| titleOfInvention | Method for treating the cases of non-resectable pancreatic carcinoma |
| abstract | FIELD: medicine. n SUBSTANCE: method involves carrying out remote gamma-therapy for treating the pancreas in individual mode. Tumor size being small, biaxial or monoaxial double-sector rotation is applied. The tumor size being greater than 10 cm, static multiple field mode is used with fractional dose supply in 2 Gr large portions twice a day with 4-5 h long pause. The total focal dose is equal to 24-28 Gr. The treatment course is repeated at a dose of 52-56 Gr after two weeks long relief pause. 2-3 weeks later, autohemochemotherapy is administered. Blood is taken in portions of 80 ml into 3 flasks with standard preservative agent. 5-fluorouracyl is introduced into the first flask keeping to concentration of 600 mg/m 2 . Doxorubicine is introduced into the second flask in the amount of 30 mg/m 2 . Mytomycine C is introduced into the third flask to provide10 mg/m 2 . The flasks are incubated at 37° C during 45 min and blood reinfusion is carried out with cytostatic reagents in known way. 80 ml of patient blood is taken at the eighth day into a flask containing preservative agent. 5-fluorouracyl is added in the amount of 600 mg/m 2 . Incubation at 37° C is carried out during 45 min and the blood is injected to the patient. Patient blood is taken into two flasks at the twenty seventh day in the amount of 80 ml in each flask mixed with a standard preservative agent. 5-fluorouracyl is added to the first flask in the amount of 600 mg/m 2 . Doxorubicine is introduced into the second flask in the amount of 30 mg/m 2 . The flasks are incubated at 37° C during 45 min and blood reinfusion is carried out in the succession order pointed out. 80 ml of patient blood is taken at the thirty sixth day into one flask containing a standard preservative agent. 5-fluorouracyl is added in the amount of 600 mg/m 2 . Incubation at 37° C is carried out during 45 min and the blood is injected to the patient. Chemotherapy preparations are given in the following quantities per course: Mytomycine C - 10 mg/m 2 , Doxorubicine - 60 mg/m 2 , 5-fluorouracyl - 2400mg/ m 2 . n EFFECT: enhanced effectiveness in reducing tumor size; high analgesic efficiency; reduced risk of complications caused by radiation and chemotherapy. n 2 dwg |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2528881-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2526802-C1 |
| priorityDate | 2002-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.